Publications by authors named "H Losonczy"

Article Synopsis
  • A study examined the immune status and infection rates in 186 patients with chronic lymphoid leukaemia from January 2012 to March 2015, focusing on those not receiving prophylactic immunoglobulin therapy.
  • High rates of hypogammaglobulinaemia were found, with 62.37% having normal IgG levels and the lowest levels linked to advanced disease stages, resulting in higher infection rates, particularly upper respiratory infections and sepsis.
  • Following chemotherapy, there was a significant drop in IgG levels, correlating with increased infections and death, primarily due to sepsis; the study suggests prophylactic immunoglobulin therapy could reduce morbidity and mortality in these patients.
View Article and Find Full Text PDF

: The diagnosis of thrombophilia is a cost-consuming and time-consuming process, as each defect should be separately investigated. The Coagulation Inhibitor Potential (CIP) assay is a promising new global test, sensitive for most of the hereditary thrombophilias, developed for manual methodology. We adapt the original method to an optical coagulation analyser.

View Article and Find Full Text PDF

Introduction: Inherited antithrombin (AT) deficiency is a heterogeneous disease. Due to low prevalence, only a few studies are available concerning genotype-phenotype associations. The aim was to describe the clinical, laboratory and genetic characteristics of AT deficiency in a large cohort including children and to add further laboratory data on the different sensitivity of functional AT assays.

View Article and Find Full Text PDF

T-cell lymphoma is a poor prognostic hematological malignancy. The generally used - not sufficiently effective - induction chemotherapy should be improved with consolidative autologous hemopoetic stem cell transplantation. The authors describe the role, place and effectiveness of transplantation in this disorder.

View Article and Find Full Text PDF

Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study.

View Article and Find Full Text PDF